Which has higher earnings & valuation, ELMD or CBLL?

Electromed has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.21 $5.15M $1.31 21.63 CeriBell $89.06M 10.71 -$53.41M -$1.76 N/A

Is ELMD or CBLL more profitable?

Electromed has a net margin of 11.34% compared to CeriBell's net margin of -64.73%. Electromed's return on equity of 15.71% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% CeriBell -64.73% -44.85% -35.69%

Which has higher valuation and earnings, SIBN or ELMD?

Electromed has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $213.60M 3.98 -$18.90M -$0.34 N/A Electromed $73.78M 3.21 $5.15M $1.31 21.63

Is SIBN or ELMD more profitable?

Electromed has a net margin of 11.34% compared to SiBone's net margin of -6.85%. Electromed's return on equity of 15.71% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Electromed 11.34% 15.71% 13.37%

Which has stronger earnings and valuation, ELMD or INMD?

InMode has higher revenue and earnings than Electromed. InMode is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.21 $5.15M $1.31 21.63 InMode $370.49M 2.21 $93.83M $1.23 11.56

Is ELMD or INMD more profitable?

InMode has a net margin of 20.69% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat InMode's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% InMode 20.69% 11.99% 10.60%

Do analysts rate ELMD or NNNN?

Electromed currently has a consensus target price of $43.75, suggesting a potential upside of 54.43%. Given Electromed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Electromed is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ELMD or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Electromed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.21 $5.15M $1.31 21.63 Anbio Biotechnology $8.65M 102.51 $6.40M N/A N/A

Electromed (ELMD) Competitors

$28.33 +0.16 (+0.57%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$28.22 -0.10 (-0.37%)

As of 09/29/2026 07:45 PM Eastern

Compare

ELMD vs. CBLL, SIBN, INMD, NNNN, and AVR

Should you buy Electromed stock or one of its competitors? Electromed's main competitors and comparable companies include CeriBell (CBLL), SiBone (SIBN), InMode (INMD), Anbio Biotechnology (NNNN), and Anteris Technologies Global (AVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Electromed compare to CeriBell?

Electromed (NYSE:ELMD) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

40.8% of Electromed shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 17.7% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Electromed has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.21	$5.15M	$1.31	21.63
CeriBell	$89.06M	10.71	-$53.41M	-$1.76	N/A

In the previous week, CeriBell had 3 more articles in the media than Electromed. MarketBeat recorded 3 mentions for CeriBell and 0 mentions for Electromed. CeriBell's average media sentiment score of 1.17 beat Electromed's score of 0.00 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
CeriBell	Positive

Electromed has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Electromed presently has a consensus price target of $43.75, suggesting a potential upside of 54.43%. CeriBell has a consensus price target of $24.40, suggesting a potential downside of 1.85%. Given Electromed's stronger consensus rating and higher probable upside, research analysts clearly believe Electromed is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Electromed has a net margin of 11.34% compared to CeriBell's net margin of -64.73%. Electromed's return on equity of 15.71% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
CeriBell	-64.73%	-44.85%	-35.69%

Summary

Electromed beats CeriBell on 9 of the 17 factors compared between the two stocks.

How does Electromed compare to SiBone?

SiBone (NASDAQ:SIBN) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Electromed has a net margin of 11.34% compared to SiBone's net margin of -6.85%. Electromed's return on equity of 15.71% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Electromed	11.34%	15.71%	13.37%

SiBone has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Electromed has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

98.1% of SiBone shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Electromed has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$213.60M	3.98	-$18.90M	-$0.34	N/A
Electromed	$73.78M	3.21	$5.15M	$1.31	21.63

SiBone currently has a consensus target price of $24.17, suggesting a potential upside of 26.20%. Electromed has a consensus target price of $43.75, suggesting a potential upside of 54.43%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, SiBone had 6 more articles in the media than Electromed. MarketBeat recorded 6 mentions for SiBone and 0 mentions for Electromed. SiBone's average media sentiment score of 0.98 beat Electromed's score of 0.00 indicating that SiBone is being referred to more favorably in the media.

Company	Overall Sentiment
SiBone	Positive
Electromed	Neutral

Summary

Electromed beats SiBone on 9 of the 16 factors compared between the two stocks.

How does Electromed compare to InMode?

Electromed (NYSE:ELMD) and InMode (NASDAQ:INMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

InMode has higher revenue and earnings than Electromed. InMode is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.21	$5.15M	$1.31	21.63
InMode	$370.49M	2.21	$93.83M	$1.23	11.56

In the previous week, InMode had 2 more articles in the media than Electromed. MarketBeat recorded 2 mentions for InMode and 0 mentions for Electromed. InMode's average media sentiment score of 0.61 beat Electromed's score of 0.00 indicating that InMode is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
InMode	Positive

Electromed has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, InMode has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

40.8% of Electromed shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InMode has a net margin of 20.69% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
InMode	20.69%	11.99%	10.60%

Electromed currently has a consensus target price of $43.75, indicating a potential upside of 54.43%. InMode has a consensus target price of $16.00, indicating a potential upside of 12.52%. Given Electromed's stronger consensus rating and higher possible upside, analysts plainly believe Electromed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
InMode	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Electromed beats InMode on 9 of the 16 factors compared between the two stocks.

How does Electromed compare to Anbio Biotechnology?

Electromed (NYSE:ELMD) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Electromed has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.17, meaning that its stock price is 417% more volatile than the broader market.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Electromed. MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Electromed. Anbio Biotechnology's average media sentiment score of 1.79 beat Electromed's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
Anbio Biotechnology	Very Positive

Electromed currently has a consensus target price of $43.75, suggesting a potential upside of 54.43%. Given Electromed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Electromed is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Electromed has a net margin of 11.34% compared to Anbio Biotechnology's net margin of 0.00%. Electromed's return on equity of 15.71% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has lower revenue, but higher earnings than Electromed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.21	$5.15M	$1.31	21.63
Anbio Biotechnology	$8.65M	102.51	$6.40M	N/A	N/A

Summary

Electromed beats Anbio Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Electromed compare to Anteris Technologies Global?

Electromed (NYSE:ELMD) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Electromed has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Electromed presently has a consensus price target of $43.75, indicating a potential upside of 54.43%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 110.80%. Given Anteris Technologies Global's higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Anteris Technologies Global had 4 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Anteris Technologies Global and 0 mentions for Electromed. Anteris Technologies Global's average media sentiment score of 1.04 beat Electromed's score of 0.00 indicating that Anteris Technologies Global is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
Anteris Technologies Global	Positive

Electromed has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.21	$5.15M	$1.31	21.63
Anteris Technologies Global	$1.91M	387.29	-$94.14M	-$1.95	N/A

Electromed has a net margin of 11.34% compared to Anteris Technologies Global's net margin of -4,619.27%. Electromed's return on equity of 15.71% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Electromed beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.

Get Electromed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELMD vs. The Competition

Export

Metric	Electromed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$237.01M	$5.56B	$7.34B	$22.88B
Dividend Yield	N/A	1.79%	2.52%	3.70%
P/E Ratio	37.77	25.35	273.78	27.68
Price / Sales	3.21	70.17	614.66	20.70
Price / Cash	41.36	32.94	80.06	41.75
Price / Book	5.55	5.72	10.44	4.61
Net Income	$5.15M	$150.11M	$3.50B	$1.07B
7 Day Performance	2.76%	-1.64%	-1.40%	-1.58%
1 Month Performance	-4.29%	-5.27%	-4.16%	-5.85%
1 Year Performance	15.40%	5.74%	12.63%	5.53%

Electromed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELMD Electromed	2.2338 of 5 stars	$28.33 +0.6%	$43.75 +54.4%	+15.4%	$237.01M	$73.78M	37.77	197
CBLL CeriBell	1.7197 of 5 stars	$24.41 +0.7%	$24.40 0.0%	+116.2%	$937.62M	$89.06M	N/A	300
SIBN SiBone	2.6579 of 5 stars	$18.81 +1.9%	$24.17 +28.5%	+35.1%	$834.45M	$200.93M	N/A	376
INMD InMode	1.736 of 5 stars	$14.47 -0.2%	$16.00 +10.6%	-5.2%	$831.45M	$370.49M	11.76	660
NNNN Anbio Biotechnology	0.9466 of 5 stars	$5.64 -0.8%	N/A	N/A	$810.82M	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELMD) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Electromed (ELMD) Competitors